By Barbara Obstoj-Cardwell. Editor
Research news last week included UK pharma major AstraZeneca and Japan’s Daiichi Sankyo releasing Phase III data for their antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) in lung cancer. Also, Veridian Therapeutics announced positive results for its thyroid eye disease candidate veligrotug. Roivant Sciences announced a collaboration with Germany’s Bayer, creating a new ‘vant’ – called Pulmovant – to in license moslicigual for pulmonary hypertension. Moderna held an R&D Day last week that failed to impress, as the company said it would cut back investment.
Phase III data on Dato-dxd
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze